Results 81 to 90 of about 910,008 (206)

NTRK Fusions Identified in Pediatric Tumors: The Frequency, Fusion Partners, and Clinical Outcome

JCO Precision Oncology, 2021
PURPOSE Neurotrophic tyrosine receptor kinase (NTRK) fusions have been described as oncogenic drivers in a variety of tumors. However, little is known about the overall frequency of NTRK fusion in unselected pediatric tumors. Here, we assessed the frequency, fusion partners, and clinical course in pediatric patients with NTRK fusion–positive tumors ...
Zhao, Xiaonan, Kotch, Chelsea, Fox, Elizabeth, Surrey, Lea F., Wertheim, Gerald B., Baloch, Zubair W., Lin, Fumin, Pillai, Vinodh, Luo, Minjie, Kreiger, Portia A., Pogoriler, Jennifer E., Linn, Rebecca L., Russo, Pierre A., Santi, Mariarita, Resnick, Adam C., Storm, Phillip B., Hunger, Stephen P., Bauer, Andrew J., Li, Marilyn M.   +18 more
openaire   +2 more sources

NTRK-A narrative review

Cancer Research, Statistics, and Treatment, 2021
Lung cancer diagnostics and therapeutics have witnessed a paradigm shift in the last decade because of the discovery of targetable biomarkers and rapid approvals of the corresponding targeted therapies.
Ullas Batra, Shrinidhi Nathany, Mansi Sharma   +2 more
doaj   +1 more source

Case report: Tracing in parallel the salivary and gut microbiota profiles to assist Larotrectinib anticancer treatment for NTRK fusion-positive glioblastoma. [PDF]

Front Oncol
Oncotherapy can shape intestinal microbiota, which, in turn, may influence therapy effectiveness. Furthermore, microbiome signatures during treatments can be leveraged for the development of personalised therapeutic protocols in cancer treatment based on
Turco L, Della Monica R, Giordano P, Cuomo M, Biazzo M, Mateu B, Di Liello R, Daniele B, Normanno N, De Luca A, Rachiglio AM, Chiaramonte C, Giugliano FM, Chiariotti L, Catapano G, Coretti L, Lembo F.   +16 more
europepmc   +2 more sources

New Measurements of Upsilon(1S) Decays to Charmonium Final States

, 2004
Using substantially larger data samples collected by the CLEO III detector, we report on new measurements of the decays of Upsilon(1S) to charmonium final states, including J/Psi, psi(2S), and chi_cJ. The latter two are first observations of these decays.
A. Bornheim, A. H. Mahmood, A. J. Sadoff, A. J. Weinstein, A. Lopez, A. Ryd, A. Smith, A. Tomaradze, A. W. Scott, B. Gittelman, B. I. Eisenstein, B. K. Heltsley, B. Sanghi, C. Boulahouache, C. D. Jones, C. J. Stepaniak, C. S. Park, C. Sedlack, D. Besson, D. Cinabro, D. Cronin-Hennessy, D. G. Cassel, D. H. Miller, D. Hertz, D. Kim, D. L. Hartill, D. L. Kreinick, D. M. Asner, D. Peterson, D. Riley, D. T. Gong, D. Urner, E. Dambasuren, E. H. Thorndike, E. I. Shibata, E. Lipeles, F. Liu, G. Bonvicini, G. D. Gollin, G. P. Chen, G. S. Adams, G. S. Huang, G. Tatishvili, H. Albrecht, H. Mahlke-Krüger, H. Mendez, H. Muramatsu, H. Schwarthoff, H. Severini, H. Stoeck, H. Vogel, I. Danko, I. Karliner, I. P. J. Shipsey, J. A. Mueller, J. B. Thayer, J. Butt, J. C. Wang, J. E. Duboscq, J. Ernst, J. G. Thayer, J. J. Thaler, J. Kandaswamy, J. L. Rosner, J. Napolitano, J. P. Alexander, J. P. Cummings, J. Pivarski, J. R. Patterson, J. Ramirez, J. Urheim, J. Williams, J. Wiss, J. Yelton, K. Arms, K. Berkelman, K. K. Gan, K. K. Seth, K. M. Ecklund, K. W. Edwards, K. Y. Gao, K. Zhang, L. Breva-Newell, L. Fields, L. Gibbons, L. Hsu, M. Artuso, M. Chasse, M. Dubrovin, M. E. Watkins, M. Kobayashi, M. R. Shepherd, M. Selen, M. Weinberger, N. E. Adam, N. Lowrey, N. Menaa, O. Dorjkhaidav, P. Avery, P. Naik, P. Rubin, P. Skubic, P. U. E. Onyisi, P. Zweber, R. A. Briere, R. Ehrlich, R. Gray, R. Mountain, R. Nandakumar, R. Patel, R. Poling, R. Redjimi, R. S. Galik, R. Sia, R. Stroynowski, S. A. Dytman, S. B. Athar, S. Baek, S. Blusk, S. E. Csorna, S. Mehrabyan, S. P. Pappas, S. Stone, S. W. Gray, S. Z. Li, T. E. Coan, T. Ferguson, T. O. Meyer, T. Skwarnicki, T. Wilksen, V. E. Kuznetsov, V. Pavlunin, V. Potlia, V. Savinov, W. M. Sun, W. Park, Y. Kubota, Y. S. Gao, Z. Li, Z. Metreveli   +139 more
core   +1 more source

NTRK Fusions in a Sarcomas Series: Pathology, Molecular and Clinical Aspects

Pathology and Oncology Research, 2022
Targeting molecular alterations has been proven to be an inflecting point in tumor treatment. Especially in recent years, inhibitors that target the tyrosine receptor kinase show excellent response rates and durable effects in all kind of tumors that ...
Vasiliki Siozopoulou, Vasiliki Siozopoulou, Elly Marcq, Koen De Winne, Koen Norga, Gertjan Schmitz, Valerie Duwel, Philippe Delvenne, Evelien Smits, Evelien Smits, Patrick Pauwels, Patrick Pauwels   +11 more
doaj   +1 more source

PD-L1, Mismatch Repair Protein, and NTRK Immunohistochemical Expression in Cervical Small Cell Neuroendocrine Carcinoma

Frontiers in Oncology, 2021
BackgroundCervical small cell neuroendocrine carcinoma (SCNC) is a rare and aggressive disease that lacks a standard treatment strategy or effective methods of targeted therapy.
Longyun Chen, Fan Yang, Ting Feng, Shafei Wu, Kaimi Li, Junyi Pang, Xiaohua Shi, Zhiyong Liang   +7 more
doaj   +1 more source

Search for Excited Quarks in $q\bar{q} \to \gamma\gamma$ at the LHC

, 2007
If quarks are composite particles, then excited states are expected to play a r\^ole in the Large Hadron Collider phenomena. Concentrating on virtual effects, and using a large part of the CMS detection criteria, we present here a realistic examination ...
Bhattacharya, Satyaki, Chauhan, Sushil S., Choudhary, Brajesh C., Choudhury, Debajyoti   +3 more
core   +1 more source

Brain Metastases From Differentiated Thyroid Cancer in the Era of Targeted Therapies: A Multi‐Center Retrospective Cohort

Head &Neck, EarlyView.
ABSTRACT Background Brain metastases (BM) of differentiated thyroid carcinoma (DTC) are associated with unfavorable prognosis. This study evaluated BM management strategies and patients' outcomes. Methods A retrospective review of patients diagnosed with DTC and BM at Tel Aviv Sourasky and Rabin Medical Centers between 1985 and 2024. Clinical features,
Liyona Kampel, Shaun Edalati, Eyal Yosefof, Anton Warshavsky, Gilad Horowitz, Nidal Muhanna, Hagit Shoffel‐Havakuk, Eyal Robenshtok, Aron Popovtzer, Inbar Finkel   +9 more
wiley   +1 more source

Prevalence, treatment response, and survival in a real-world NTRK gene fusion-positive microsatellite instability-high metastatic colorectal cancer cohort

ESMO Real World Data and Digital Oncology
Background: Tropomyosin receptor kinase (TRK) inhibitors are approved for patients with neurotrophic tyrosine receptor kinase (NTRK) fusion-positive solid tumors, but clinical benefit in metastatic colorectal cancer (mCRC) is uncertain.
S.J. Schraa, M.M. Laclé, K. Zwart, E.H. Gort, W.W. de Leng, M. Koopman, G.R. Vink, G.M. Bol   +7 more
doaj   +1 more source

J/Psi production as a function of charged particle multiplicity in pp collisions at sqrt{s}=7 TeV with the ALICE experiment

, 2011
We report on the first measurement of J/Psi production as a function of charged particle pseudo-rapidity density dN_ch/d_eta in pp collisions at sqrt{s} = 7 TeV with the ALICE experiment at the LHC.
Porteboeuf-Houssais, Sarah
core   +3 more sources